• Wayne L Miller, Diane E Grill, and Allan S Jaffe.
• Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA. miller.wayne@mayo.edu
• Clin. Chim. Acta. 2012 May 18; 413 (9-10): 920-6.

BackgroundHeart failure (HF) progression and outcomes reflect activation of multiple neurohormonal systems. Which biomarkers reflecting these systems contribute incremental information remains unclear. The aim of this study was to determine if serial measurements of pro-BNP(1-108) separately, in combination with standard assay BNP, or with troponin T (cTnT) would enhance risk stratification in ambulatory HF patients.MethodsA cohort of 187 Class III-IV HF patients was prospectively studied. Blood was collected every 3 months over 2 years for biomarker analysis [pro-BNP(1-108), standard assay BNP, troponin T (cTnT)] in relation to the primary endpoint of death or cardiac transplantation.ResultsUnivariate categorical and continuous variable analyses of single-sample and time-dependent serial values of pro-BNP(1-108) and BNP demonstrated that elevations in both biomarkers were associated with increased risk of death/transplantation. Multivariate analysis of serial measurements adjusted for cTnT revealed cTnT as the independent marker of risk. Combined elevations of either pro-BNP(1-108) or BNP with cTnT, however, were the most significant predictors of outcome.ConclusionsCirculating levels of pro-BNP(1-108) appear to be comparable to mature BNP in ambulatory HF out-patients. Elevated levels of pro-BNP(1-108) or BNP identified by serial monitoring similarly predict events. A strategy of serial monitoring of either pro-BNP(1-108) or BNP alone or particularly in combination with cTnT can serve a valuable role in detecting higher-risk HF patients.Copyright © 2012 Elsevier B.V. All rights reserved.

18 keywords...

hide…